PFG Investments LLC decreased its holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 90.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 18,900 shares of the company's stock after selling 170,130 shares during the quarter. PFG Investments LLC's holdings in Ginkgo Bioworks were worth $186,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. Algert Global LLC bought a new stake in Ginkgo Bioworks during the second quarter worth about $36,000. SG Americas Securities LLC bought a new stake in shares of Ginkgo Bioworks during the 4th quarter worth approximately $199,000. Mackenzie Financial Corp bought a new position in Ginkgo Bioworks in the second quarter valued at approximately $251,000. Point72 Asia Singapore Pte. Ltd. raised its position in Ginkgo Bioworks by 644.5% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 32,319 shares of the company's stock valued at $263,000 after purchasing an additional 27,978 shares in the last quarter. Finally, FNY Investment Advisers LLC boosted its holdings in shares of Ginkgo Bioworks by 125.6% in the 4th quarter. FNY Investment Advisers LLC now owns 75,966 shares of the company's stock valued at $745,000 after purchasing an additional 42,298 shares in the last quarter. Institutional investors own 78.63% of the company's stock.
Ginkgo Bioworks Trading Up 14.6 %
Shares of Ginkgo Bioworks stock traded up $2.09 during trading on Wednesday, reaching $16.38. 2,982,512 shares of the company's stock were exchanged, compared to its average volume of 1,437,726. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $5.26 and a 1-year high of $64.40. The stock has a market cap of $941.52 million, a P/E ratio of -1.25 and a beta of 1.16. The company has a 50-day simple moving average of $10.73.
Ginkgo Bioworks Profile
(
Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Featured Articles
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
